Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lymphoma: glofitamab under Real-World microscope

NCT ID NCT07472621

Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well the drug glofitamab works for people with a type of blood cancer called diffuse large B-cell lymphoma that did not respond to or came back after initial treatment. About 20 adults will take part, and their doctors will decide if they get glofitamab alone or with other drugs. The goal is to see how many patients have their tumors shrink or disappear, while also tracking side effects and using a blood test to check for leftover cancer cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include adult patients (≥18 years) with histologically confirmed diffuse large B-cell lymphoma (DLBCL) who have primary refractory disease or early relapse after first-line therapy. Eligible patients are those who plan to initiate a glofitamab-containing treatment regimen (either as monotherapy or in combination with other agents) in routine clinical practice. Patients will be enrolled from participating centers and followed prospectively to evaluate treatment outcomes and safety in a real-world setting.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must meet all of the following criteria: 1. Age ≥18 years at the time of treatment initiation. 2. Histologically or pathologically confirmed diffuse large B-cell lymphoma (DLBCL). 3. Patients with primary refractory disease or early relapse, defined as: Failure to achieve complete response (CR) after at least 4 cycles of first-line induction therapy, or Relapse confirmed by imaging within 12 months after achieving CR following first-line therapy. 4. Patients who plan to initiate a glofitamab-containing treatment regimen (either monotherapy or combination therapy) within 12 months after study initiation. 5. Willing and able to comply with study follow-up and data collection requirements. Exclusion Criteria: * Participants meeting any of the following criteria will be excluded: 1. Currently participating in, or planning to participate in, any interventional clinical trial. 2. Any condition that, in the investigator's judgment, would make the patient unsuitable for participation in this study (e.g., inability to complete follow-up, safety concerns, or significant comorbidities).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL - diffuse large B cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma interdigitating dendritic cell sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DLBCL - diffuse large B cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Henan cancer hospital

    Zhengzhou, Henan, 450008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.